| Document |
Document Title |
|
WO/2011/145068A1 |
The present invention relates to a compound of general formula (I) in which: - X is OH, NH2, NHOH or RNH, wherein R may be a linear or branched, saturated or unsaturated, C1-C10 alkyl radical, - Y is H, or an electron-withdrawing group, ...
|
|
WO/2011/145519A1 |
Disclosed are methods for producing a glucoside directly from glucose or a sugar chain comprising glucose as a structural unit. Specifically disclosed are: a method which comprises reacting glucose or a sugar chain comprising glucose as ...
|
|
WO/2011/143497A1 |
The present invention relates to antimicrobial and antibiotic aminoglycoside derivatives. The compounds of the present application have the following chemical structures. The invention also relates to compositions, methods of preparation...
|
|
WO/2011/138365A1 |
A process for the preparation of 1,6-Bis-[3-(3-carboxymethylphenyl)-4-(2-α-D-mannopyranosylo
xy)-phenyl] hexane (I) which comprises the steps of converting the compound (2'-Methoxy-biphenyl-3-yl)-acetic acid (A) into the (2'-Methoxy-bip...
|
|
WO/2011/137181A1 |
The present invention provides synthetic Moraxella catarrhalis lipooligosaccharide (LOS)-based oligosaccharides and conjugates containing various M. catarrhalis serotype-specific oligosaccharide antigens or various core M. catarrhalis ol...
|
|
WO/2010/132760A9 |
Compounds having antibacterial activity are disclosed. The compounds have the following structure (I): including stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, wherein Q1, Q2, Q3, R1, R2 and R3 are as defined here...
|
|
WO/2011/133227A2 |
The present invention synthetic oligo-β-(1→6)-glucosamine structures and a methodology which essentially allows for the synthesis of any oligo-β-(1→6)- glucosamine species having a definite number of monosaccharide units, including...
|
|
WO/2010/132765A9 |
Antibacterial compounds of structures (I) and (II) are disclosed, including stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, wherein Q1, Q2, Q3, R1, R2, R3, R11 are as defined herein. Methods associated with prepara...
|
|
WO/2011/125057A1 |
The invention relates to novel eucomic acid (2-(4-hydroxybenzyl)malic acid) derivatives or plant extracts comprising such derivatives, and also to cosmetic or dermatological compositions containing these compounds or these extracts, and ...
|
|
WO/2011/127179A1 |
Compounds, compositions and methods are provided for use to inhibit infection by human immunodeficiency virus (HIV). More specifically, the present invention relates to glycomimetic compounds that inhibit HIV infection, and uses thereof.
|
|
WO/2011/118929A2 |
The present invention relates to the crystal form of Epirubicin hydrochloride stable against heat and water and the preparation method thereof. The novel crystal form has the physiochemical property stable against heat and water accordin...
|
|
WO/2011/113373A1 |
Disclosed is a method for ultrasonic extraction of stevioside. Crushed dry leaves of Stevia rebaudiana serve as raw material. Based on the characteristic that an ultrasonic cavitation can reinforce the extraction of active ingredients in...
|
|
WO/2010/132768A9 |
Antibacterial compounds of structure (I) are disclosed, including stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, wherein Q1, Q2, Q3, R11 and R12 are as defined herein. Methods associated with preparation and use o...
|
|
WO/2010/132839A9 |
The present invention provides new aminoglycoside dosing regimens associated with enhanced microbicidal activity and reduced nephrotoxicity, as well as methods of using these dosing regimens to treat various bacterial infections.
|
|
WO/2011/110721A1 |
The invention relates to a method for obtaining surfactants from cellulose and hemicellulose, which comprises one reaction in a single reactor (one pot) and which includes at least the following steps: e) a first hydrolysis step, in whic...
|
|
WO/2010/132759A9 |
Compounds having antibacterial activity are disclosed. The compounds have the following structure (I): including stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, wherein Q1, Q2, Q3, R1, R2 or R3 are as defined herei...
|
|
WO/2011/100980A1 |
The present invention relates to a method for preparation of the tetrasaccharide lacto-N-neotetraose (LNnt, formula (I)) especially in large scale, as well as intermediates in the synthesis, a new crystal form (polymorph) of LNnt, and th...
|
|
WO/2011/100979A1 |
The present invention relates to a method for preparation of the trisaccharide 6'-0-sialyllactose (formula (I)) or salts thereof as well as intermediates in the synthesis and for the use of 6'-0-sialyllactose salts in pharmaceutical or n...
|
|
WO/2011/098417A1 |
Substituted cyanobutyrates of the formula I in which the variables are defined according to the description, processes and intermediates for preparing the compounds of the formula I and their N-oxides, their agriculturally suitable salts...
|
|
WO/2011/096536A1 |
Disclosed is a compound represented by general formula (1) or a salt thereof, which is capable of preferentially inducing the production of IFN-γ in NKT cells and is therefore useful for the prevention or treatment of cancer or infectio...
|
|
WO/2011/096484A1 |
A read through inducer for an immature termination codon formed by a nonsense mutation, which comprises a compound represented by structure formula (A); and a therapeutic agent for nonsense-mutation-type genetic diseases, which comprises...
|
|
WO/2011/096374A1 |
Provided is a novel iodobenzyl-bleomycin compound. Also provided are metal complexes that consist of the iodobenzyl-bleomycin compound and various metal atoms, such as an iodobenzyl-Co-bleomycin compound, that can accumulate on malignant...
|
|
WO/2011/093471A1 |
Provided is a method for producing neoponkoranol or an analog thereof represented by structural formula [I] [wherein X- stands for a conjugated base of a Bronsted acid HX such as a carboxylate ion represented by R1COO-, a sulfonate ion r...
|
|
WO/2011/094702A1 |
Steviol glycoside agglomerate compositions are disclosed that do not include binding agents or carriers.
|
|
WO/2011/089561A1 |
A method of preparing a compound of formula (I): wherein: a first group selected from R1, R2 and R3 is an amino- or N-acylamino monosaccharide moiety, the acyl group having 1 to 6 carbon atoms, or an oligosaccharide chain comprising 2 to...
|
|
WO/2011/088843A1 |
The present invention relates to enterococcal cell wall components and their uses in the prevention and therapy of bacterial infection.
|
|
WO/2011/089602A2 |
The present invention relates to anthracycline derivatives that are based on an Aloe-emodin (AE) backbone attached to a glycoside (an amino sugar or amino carba-sugar). These derivatives are useful as chemotherapeutic agents. Advantageou...
|
|
WO/2011/085544A1 |
Compounds which effectively remove tumor or cancer cell and their use for the treatment and prevention of tumor or cancer by making immune system find tumor or cancer cell are provided. In detail, by immune identifier of tumor or cancer ...
|
|
WO/2011/082288A1 |
Exemplary embodiments of this invention encompass a method for purifying a low purity steviol glycoside composition. In particular, this invention relates to a method for purifying low purity steviol glycoside compositions to obtain subs...
|
|
WO/2011/076625A1 |
The invention relates to a sweetener and to a method for the production thereof.
|
|
WO/2011/078383A1 |
Provided is a liquid-crystal compound which is usable as a base for injections. The compound is an amphipathic compound represented by general formula (I), wherein X and Y each represents a hydrogen atom or X and Y in cooperation represe...
|
|
WO/2011/073112A2 |
Compounds of the formula (I) wherein n is 0, 1 or 2, R1 is aryl, heteroaryl or heterocyclyl, and R2 and R3 are hydrogen or a substituent as described in the specification, are useful for the prevention and treatment of bacterial infectio...
|
|
WO/2011/066653A1 |
Salacinol and ponkoranol homologues, derivatives thereof and methods of synthesizing and using said homologies and derivatives. The derivatives include stereoisomers, de-O-sulfonated compounds and congeners of the naturally occurring hom...
|
|
WO/2011/058245A1 |
The present invention relates to mannopyranoside-derived compounds and to the use thereof as medicaments, in particular in the treatment of cancer diseases, and also to the method for preparing same and to pharmaceutical compositions com...
|
|
WO/2011/058661A1 |
Provided is a method for extracting isosaponarin at a high concentration from wasabi (Wasabia japonica) leaves. Also provided is a method for extracting a material for foods, drugs and cosmetics. Isosaponarin is extracted at a high conce...
|
|
WO/2011/056834A2 |
Thermally stable anhydrous Rebaudioside D can be provided by methods disclosed here and has been found to be more soluble in aqueous solutions than the previously known non-anhydrous Rebaudioside D. This physical property makes the anhyd...
|
|
WO/2011/052919A2 |
The present invention relates to alpga-galactosylceramide derivatives, to the pharmaceutically acceptable salts thereof, to a method for preparing same, and to a pharmaceutical composition for an immune adjuvant, containing the derivativ...
|
|
WO/2011/051520A1 |
The present invention relates to novel triterpenic saponins from the saffron (Crocus sativus L.) corm, a composition that comprises said saponins, the use thereof as adjuvant substances in protein vaccines, and also in the production of ...
|
|
WO/2011/048148A2 |
This invention relates to compounds represented by formula (I) wherein the variables are defined as herein above, which are useful for treating diseases and conditions mediated by the sodium D-glucose co-transporter (SGLT), e.g. diabetes...
|
|
WO/2011/044751A1 |
Foliamangiferosides having the general formula (I) are disclosed, wherein R is H or -OCH3. The preparation method of the compounds, pharmaceutical compositions comprising the compounds as the active ingredients, the use of the compounds ...
|
|
WO/2011/046057A1 |
Provided is a novel and non-natural sialic acid-containing sugar chain compound, which has a binding activity to a viral particle and remains stable even in the presence of sialidase, obtained by using a reaction with the use of a glycos...
|
|
WO/2011/039107A1 |
The invention relates to a method for the preparation for a crystalline form of 1-chloro-4-(Β-D-glucopyranos-1-yl)-2-[4-((S)-tetrahydrofura
n-3-yloxy)-benzyl]-benzene. In addition the invention relates to a crystalline form obtainable b...
|
|
WO/2011/038356A2 |
This invention provides novel liver targeting agents and their synthetic methods. A liver targeting agent, with a lysine based nitrilo triacetic acid structure as backbone which acquires multivalency with saccharide groups, to bind with ...
|
|
WO/2011/035518A1 |
Pyrimidine derivatives and analogs, their pharmaceutically acceptable salts, processes for preparing them, pharmaceutical compositions comprising them, and their use in manufacture of medicaments for treating inflammatory and infectious ...
|
|
WO/2011/029576A1 |
The present invention relates to a form of crystalline 4'-epidaunorubicin hydrochloride which is stable and readily soluble, and to a process for the production thereof. This process comprises crystallizing 4'-epidaunorubicin hydrochlori...
|
|
WO/2011/025286A2 |
The present invention relates to lipoteichoic acid-derived glycolipids, and to pharmaceutical, food or cosmetic compositions and vaccine adjuvants comprising same. The lipoteichoic acid-derived glycolipids according to the present invent...
|
|
WO/2011/017998A1 |
Gambogic acid cyclization analogues with formula I, II and III are disclosed, wherein cycles A, B and C are saturated or unsaturated alicyclic, alicyclic heterocyclic, aromatic ring or aromatic heterocyclic groups containing 4-10 members...
|
|
WO/2011/019419A1 |
Tumors can be selectively targeted via compounds provided herein according to the formula, or a pharmaceutically acceptable salt thereof, wherein RA and RB are as defined herein. Tumors can be imaged or targeted for therapeutic treatment...
|
|
WO/2011/016558A1 |
Disclosed is a method for easily and economically producing a highly pure glucosylceramide-containing material in a large amount from a plant material. A highly pure glucosylceramide can be obtained in a large amount by a method for prod...
|
|
WO/2011/006237A1 |
Compounds of structural formula (I) useful for the treatment or prophylaxis of viral infection, particularly viral influenza are provided Pharmaceutical preparations thereof and methods for their preparation are also described. The thera...
|
